TY - JOUR
KW - Buprenorphine/therapeutic use
KW - Consensus
KW - Europe
KW - Humans
KW - Mental Disorders/complications/diagnosis
KW - Methadone/therapeutic use
KW - Opiate Substitution Treatment
KW - Opioid-Related Disorders/complications/drug therapy
KW - Patient Preference
KW - Quality of Life
KW - Risk Reduction Behavior
KW - buprenorphine
KW - Methadone
KW - opioid agonist therapy
KW - opioid use disorder
AU - Maurice Dematteis
AU - Marc Auriacombe
AU - Oscar D'Agnone
AU - Lorenzo Somaini
AU - Nestor Szerman
AU - Richard Littlewood
AU - Farrukh Alam
AU - Hannu Alho
AU - Amine Benyamina
AU - Julio Bobes
AU - Jean Pierre Daulouede
AU - Claudio Leonardi
AU - Icro Maremmani
AU - Marta Torrens
AU - Stephan Walcher
AU - Michael Soyka
A1 - 
AB - INTRODUCTION: Management of patients with opioid use disorder (OUD) commonly includes opioid agonist therapy (OAT) as a part of an integrated treatment plan. These interventions are associated with proven benefits to the individual and society. Areas covered: The use of methadone and buprenorphine within an integrated treatment plan in the management of patients with OUD: this work provides consensus recommendation on pharmacotherapy in OUD to assist clinicians with practical decision making in this field. Expert opinion: Pharmacotherapy is recommended as part of an integrated OUD treatment approach with psychosocial interventions, with the goal of reducing risks of illicit opioid use, overdose mortality, infection with HIV or HCV, improving health, psychological and social outcomes. Access to OAT should be prioritised in the treatment of OUD. Treatment choices in OUD pharmacotherapy should be based on the needs of the individual and characteristics of medications. Recommendations for choices of OAT are based on clinical efficacy, safety, patient preference, side effects, pharmacological interactions, quality of life, dose titration potential and outcomes (control craving, ongoing opioids consumption or other drugs, and potentially psychiatric comorbidities). Special groups, pregnant women, prisoners, patients with mental health problems have specific needs which must be addressed with expert input.
AD - a Department of Addiction Medicine , Grenoble Alpes University Hospital , Grenoble , France.; b Faculty of Medicine , Grenoble Alpes University , Grenoble , France.; c Universite de Bordeaux , Bordeaux , France.; d Addiction Psychiatry Team , SANPsy CNRS USR , Bordeaux , France.; e Pole Addictologie, CH Ch. Perrens and CHU Bordeaux , Bordeaux , France.; f Faculty of Medical and Human Sciences , Institute of Brain Behaviour and Mental Health, University of Manchester , Manchester , UK.; g Addiction Treatment Centre , Biella , Italy.; h Department of Psychiatry , Hospital Universitario Gregorio Maranon , Madrid , Spain.; i Applied strategic , London , UK.; j Divisional Medical Director, Central & North West London NHS Foundation Trust , London , UK.; k Abdominal Center , University Hospital and University of Helsinki , Helsinki , Finland.; l Centre d'Enseignement, de Recherche et de Traitement des Addictions, AP-HP, Paris-Sud University Hospital Group, Paul Brousse site , Paris-Sud University , Villejuif , France.; m Department of Psychiatry , University of Oviedo-CIBERSAM , Oviedo , Spain.; c Universite de Bordeaux , Bordeaux , France.; d Addiction Psychiatry Team , SANPsy CNRS USR , Bordeaux , France.; n Centre dAddictologie, BIZIA and CH Bayonne , Bayonne , France.; o Drug Addiction Department , Local Public Health ASL Rome 2 , Rome , Italy.; p Santa Chiara University Hospital , University of Pisa , Pisa , Italy.; q Department of Psychiatry and Legal Medicine , Universidad Autonoma de Barcelona, Institut de Neuropsiquiatria i Addiccions, Hospital del Mar, IMIM (Hospital del Mar Medical Research Institut) , Barcelona , Spain.; r CONCEPT, Addiction Medicine , Munich , Germany.; s Department of Psychiatry , Ludwig Maximilian University , Munich , Germany.; t Medical Park Ciemseeblick , Bernau-Felden , Germany.
BT - Expert opinion on pharmacotherapy
C5 - Education & Workforce; Opioids & Substance Use
CP - 18
CY - England
DO - 10.1080/14656566.2017.1409722
IS - 18
JF - Expert opinion on pharmacotherapy
LA - eng
M1 - Journal Article
N2 - INTRODUCTION: Management of patients with opioid use disorder (OUD) commonly includes opioid agonist therapy (OAT) as a part of an integrated treatment plan. These interventions are associated with proven benefits to the individual and society. Areas covered: The use of methadone and buprenorphine within an integrated treatment plan in the management of patients with OUD: this work provides consensus recommendation on pharmacotherapy in OUD to assist clinicians with practical decision making in this field. Expert opinion: Pharmacotherapy is recommended as part of an integrated OUD treatment approach with psychosocial interventions, with the goal of reducing risks of illicit opioid use, overdose mortality, infection with HIV or HCV, improving health, psychological and social outcomes. Access to OAT should be prioritised in the treatment of OUD. Treatment choices in OUD pharmacotherapy should be based on the needs of the individual and characteristics of medications. Recommendations for choices of OAT are based on clinical efficacy, safety, patient preference, side effects, pharmacological interactions, quality of life, dose titration potential and outcomes (control craving, ongoing opioids consumption or other drugs, and potentially psychiatric comorbidities). Special groups, pregnant women, prisoners, patients with mental health problems have specific needs which must be addressed with expert input.
PP - England
PY - 2017
SN - 1744-7666; 1465-6566
SP - 1987
EP - 1999
EP - 
T1 - Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus
T2 - Expert opinion on pharmacotherapy
TI - Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus
U1 - Education & Workforce; Opioids & Substance Use
U2 - 29183228
U3 - 10.1080/14656566.2017.1409722
VL - 18
VO - 1744-7666; 1465-6566
Y1 - 2017
Y2 - Dec
ER -